Demyelinating disease of the central nervous system associated with Pembrolizumab treatment for metastatic melanoma. (June 2019)

• Record Type: Journal Article
• Authors: Durães, João; Coutinho, Inês; Mariano, Angelina; Geraldo, Argemiro; Macário, Maria Carmo
• Is Part Of: Multiple sclerosis. Volume 25:Number 7(2019)
• Page Start: 1005
• Page End: 1008
• Publication Date: 2019-06
• Subjects: Demyelination -- immune checkpoint inhibitors -- immunology -- Pembrolizumab; Central nervous system -- Diseases -- Periodicals; Myelin sheath -- Diseases -- Periodicals; Inflammation -- Periodicals; Multiple sclerosis -- Periodicals; Central Nervous System Diseases -- Periodicals; Demyelinating Diseases -- Periodicals; Inflammation -- Periodicals; Multiple Sclerosis -- Periodicals; Système nerveux central -- Maladies -- Périodiques; Gaine de myéline -- Maladies -- Périodiques; Inflammation (Pathologie) -- Périodiques; Sclérose en plaques -- Périodiques; Electronic journals; 616.834005
• DOI: 10.1177/1352458518803724
• Languages: English
• ISSNs: 1352-4585

Abstract

Immune checkpoint inhibitors are used in metastatic melanoma with good efficacy and safety profile. We report the first case of an inflammatory demyelinating disease of the central nervous system during treatment with Pembrolizumab and discuss the evidence in the literature supporting its causative role. The patient had a good clinical recovery after intravenous steroids, plasma exchange and discontinuation of Pembrolizumab. Due to the expected increase in the importance of immune checkpoint inhibitors in cancer treatment, it is important to be aware of neurological adverse events, as early treatment usually leads to good clinical responses.